Escalon Medical Corp. Reports Decrease in Revenue and Increased Net Loss for Quarter Ended September 30, 2025

Escalon Medical Corp. reported a decrease in financial performance for the three months ended September 30, 2025, with net revenues of $2.68 million, down 3.8% from $2.78 million in the same period last year. The decline was primarily driven by a $129,000 drop in sales of Sonomed products and a $15,000 decrease in Trek product sales, although AXIS net revenue increased by $38,000. The company's cost of revenue was approximately $1.55 million, representing 58.1% of total revenue, compared to 56.4% in the prior year, indicating a slight increase in costs relative to revenue.

The company reported a net loss of $239,852 for the quarter, significantly higher than the loss of $32,217 recorded in the same period of 2024. This loss was attributed to increased research and development expenses, which rose by 53.2% to $216,000, reflecting investments in new product development. Marketing, general, and administrative expenses also saw a minor increase of 0.7% to $1.11 million, driven by higher payroll and advertising costs, partially offset by a credit loss adjustment.

In terms of operational metrics, Escalon's total current assets decreased to $4.22 million from $4.61 million at the end of June 2025, while current liabilities also fell to $2.53 million from $2.69 million. The company's working capital decreased to $1.69 million, and its current ratio slightly declined to 1.67 from 1.72. The accumulated deficit increased to approximately $68.68 million, raising concerns about the company's ability to continue as a going concern, especially given the historical trend of recurring losses and negative cash flows from operations.

Escalon's strategic focus includes enhancing its product offerings and exploring partnerships to mitigate financial challenges. The company is actively monitoring market conditions, including the impact of recent tariffs on imported materials, which could affect profitability and supply chain dynamics. In November 2025, Escalon entered into a loan agreement for $100,000 to support working capital needs, indicating ongoing efforts to secure financing amid operational challenges.

Looking ahead, Escalon Medical Corp. aims to stabilize its financial position by managing costs and pursuing additional capital-raising opportunities. The company acknowledges the uncertainty surrounding its future profitability and cash flow generation, emphasizing the need for strategic planning and potential adjustments to its operational framework to navigate the evolving market landscape.